Drug Profile
Research programme: anti-tau antibodies - Eli Lilly and Company
Alternative Names: AT 8 antibody; DA 9 antibody; MC 1 antibody; PHF 1 antibodyLatest Information Update: 28 Aug 2021
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antidementias; Monoclonal antibodies
- Mechanism of Action Tau protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Alzheimer's disease
Most Recent Events
- 28 Aug 2021 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (Injection)
- 16 Jul 2017 Updated pharmacodynamics data from a preclinical trial in Alzheimer's disease presented at the Alzheimer's Association International Conference (AAIC-2017)
- 12 Jul 2017 Preclinical trials in Alzheimer's disease in USA (Parenteral) before July 2017